1397
Porcine factor VIII (pFVIII), which is used to control bleeding in patients with congenital or acquired haemophilia who have high-titre neutralizing antibodies to human FVIII, is not known to increase the risk of arterial or venous thrombosis.
 ( adverse event: increase ,  patients with congenital or acquired haemophilia who have high-titre neutralizing antibodies to human FVIII: Subject, risk of arterial or venous thrombosis.: Effect, Porcine factor VIII (pFVIII): Treatment, high-titre neutralizing antibodies to human FVIII: Treatment.Disorder, bleeding: Treatment.Disorder, congenital or acquired haemophilia: Treatment.Disorder, Porcine factor VIII: Treatment.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( adverse event: increase ,  patients with congenital or acquired haemophilia who have high-titre neutralizing antibodies to human FVIII: Subject, risk of arterial or venous thrombosis.: Effect, Porcine factor VIII (pFVIII): Treatment, high-titre neutralizing antibodies to human FVIII: Treatment.Disorder, bleeding: Treatment.Disorder, congenital or acquired haemophilia: Treatment.Disorder, Porcine factor VIII: Treatment.Drug) 